STO · SPRINT.ST
Sprint Bioscience AB
SEK 3.50+SEK 0.06 (+1.74%)
Sprint Bioscience AB’s quoted price sits in the upper half of its reported 52-week range, 23.75% below the high.
Loading market information…
STO · IDLDX.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:17 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
IDL Diagnostics AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 37.17% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
IDL Diagnostics AB (publ)’s next earnings report is currently expected on Nov 5, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow IDL Diagnostics AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Specializing in in vitro diagnostics (IVD), IDL Diagnostics AB (publ) develops and markets diagnostic tests aimed at detecting cancer and bacterial infections within the Swedish market. Its product portfolio includes UBC Rapid, a point-of-care solution for both diagnosing and tracking bladder cancer; AroCell TK 210 ELISA, utilized as a biomarker for identifying tumor cells; and TUBEX TF, an in vitro diagnostic tool for pinpointing acute typhoid fever. Formerly operating as AroCell AB (publ), the company is scheduled to adopt the name IDL Diagnostics AB (publ) in May 2025. Established in 2000, its operations are headquartered in Stockholm, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2024 |
|---|
| Oct 24, 2024 |
| -SEK 0.04 |
| SEK 14.00M-7.92% vs estimate |
| Q2 2024 | Aug 21, 2024 | -SEK 0.06 | SEK 15.27M+12.3% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 3.50+SEK 0.06 (+1.74%)
Sprint Bioscience AB’s quoted price sits in the upper half of its reported 52-week range, 23.75% below the high.
SEK 16.70-SEK 0.20 (-1.18%)
Scandinavian Real Heart AB (Publ)’s quoted price sits in the lower half of its reported 52-week range, 29.54% below the high.
SEK 1.25SEK 0.00 (0.0%)
Iconovo AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 31.69% below the high.
SEK 3.83+SEK 0.03 (+0.66%)
Active Biotech AB’s quoted price sits in the lower half of its reported 52-week range, 59.44% below the high.
SEK 1.57+SEK 0.01 (+0.32%)
Pila Pharma AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 37.4% below the high.
SEK 0.04+SEK 0.00 (+0.5%)
Spago Nanomedical AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 80.95% below the high.
SEK 0.04-SEK 0.03 (-36.78%)
Immunovia AB’s quoted price sits in the lower half of its reported 52-week range, 87.62% below the high.
SEK 0.02+SEK 0.00 (+2.61%)
SpectraCure AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 93.5% below the high.
